Bharat Biotech inks tech transfer pact with Biofabri for MTBVAC TB vaccine

Bharat Biotech has signed a technology transfer agreement with Spain's Biofabri to enable end-to-end manufacturing of MTBVAC, with a Phase 3 study in India expected to start recruitment in Q1 2026

Bharat Biotech International (BBIL) on Monday inked a technology transfer agreement with Spanish vaccine maker Biofabri to advance global access for MTBVAC, a vaccine candidate that has progressed into advanced clinical development for tuberculosis (TB) in newborns, adolescents and adults.

 

What does the new agreement add to the 2022 licensing deal? 

The pact comes three years after the companies first signed a licensing agreement in 2022. “The technology transfer process has already begun to ensure BBIL’s manufacturing readiness by the time of MTBVAC licensure in India,” the companies said in a statement.

 

They added that the partnership strengthens long-term collaboration